← Leaderboards
Aditya N Bade
University Of Nebraska Medical Center
$2,497,932
Attributed
$2,708,994
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,708,994 · 4
By mechanism
R01$1,865,264 · 2
R21$843,730 · 2
Top collaborators
- Yutong Liu1 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Alexander V Kabanov$28,176,125
- Serguei V Vinogradov$4,193,151
- Paras Kumar Mishra$4,117,236
- Tatiana K Bronich$14,219,791
- Bernard Timothy Baxter$6,986,380
Others in their field
Other Emerging Leaders on “Blood”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Susan M Landau · University Of California Berkeley$47,252,026
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
Research focus
BloodIn UteroPregnantToxic EffectMagnetic Resonance ImagingDrug KineticsImpairmentPregnancyPregnant WomenRegimenNeurodevelopmentAnti-Retroviral AgentsMothersLinkHiv-1FetalPharmaceutical PreparationsClinically RelevantApoptosisCountryClinical ResearchDevelopmental NeurotoxicityCell ProliferationEmbryo
Grant awards (6)
Synergistic Effect of Nicotine and Antiretrovirals on Placental Development$718,374
R01 · FY2025 · DA · contact PI
Integrase Inhibitors during pregnancy and Neurodevelopmental Outcomes: Underlying Mechanism and Therapeutic Intervention$573,445
R01 · FY2025 · HD · contact PI
Imaging Biomarker for Determining Antiretroviral-induced Neurodevelopmental Impairments$422,125
R21 · FY2025 · HD · contact PI
Integrase Inhibitors during pregnancy and Neurodevelopmental Outcomes: Underlying Mechanism and Therapeutic Intervention$573,445
R01 · FY2024 · HD · contact PI
Functional mechanism underlying Dolutegravir (DTG)-associated developmental CNS abnormalities: Inhibition of matrix metalloproteinases activities$230,250
R21 · FY2022 · HD · contact PI
Functional mechanism underlying Dolutegravir (DTG)-associated developmental CNS abnormalities: Inhibition of matrix metalloproteinases activities$191,355
R21 · FY2021 · HD · contact PI